NeuroPace reports 2021 revenue $45.2M (+10% YoY), Q4 net loss $10.7M

NeuroPace Inc

Full-year initial implant revenue $33.7M (+20% YoY); replacement revenue $11.5M (-12% YoY).
Q4 total revenue $11.0M (+2% YoY); net loss $10.7M vs $4.6M loss in Q4 2020.
FDA approved IDE for pivotal study in drug-resistant primary generalized epilepsy.
2022 guidance: full-year revenue $45-48M, initial implant revenue $39-42M.
Cash and marketable securities $115.6M; long-term borrowings $49.8M as of Dec 31, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.